<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药渡 | wechat-feeds</title><link>http://MzA5MjEzODQ3NA.favicon.privacyhide.com/favicon.ico</link><description>药渡以自有药物大数据为依托，对上市及临床在研药物、药物研究进展和重要药物市场商业动态作出信息整合分析，传递药物创新一手资讯</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 02 Mar 2021 07:39:10 +0800</pubDate><image><url>http://MzA5MjEzODQ3NA.favicon.privacyhide.com/favicon.ico</url><title>药渡 | wechat-feeds</title><link>http://MzA5MjEzODQ3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>结合QbD分析如何运用DOE对处方进行设计</title><link>https://mp.weixin.qq.com/s/RXzpiT8aq_hA7T2xAl6L_Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu0UnoH91yzvrqibWPygzDUv0pN46wM54PM3wYXDeguPeCgicT4oYfQ12moSLNdFkcVk38u2sZm5bibpQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>DOE即Design of Experimental实验设计，是一种籍用实验的手段来决定最佳设计或生产的方法。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>四月申城 · 牛年最New阵容：生物药领域千人盛会BioCon带你“一览乾坤”！</title><link>https://mp.weixin.qq.com/s/zzPSJvIeiS1Q4gddp5Cz6Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu0UnoH91yzvrqibWPygzDUv0yZfwT7x69s0jcu8cr0bJicYZJnAl14XVpIGVCBib7VnYndZ2Qo5uOYqA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>友情提示：含“剧透”哦]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>Cytiva赋能生物制药系列课程第2课：加速新型抗体药物开发策略</title><link>https://mp.weixin.qq.com/s/FZJV-3-C_2CpbvdVqFv1tw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu0aMOyicsgDX1DR1hBL5ibIicHQb5AMh5SsTzJPfeF7MByRiarh7QQct6Iial770pahUISO8WYrHMhYgag/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>3月3日晚19:30，直播间不见不散！]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>百济神州2020年财报：收入3亿美元，研发费用13亿美元，在亏损扩大中迎来12款商业化产品</title><link>https://mp.weixin.qq.com/s/0adadaf9OvKqhI8pZpz_Fg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu0UnoH91yzvrqibWPygzDUv0deCalutkwxSkL5P9NoyNice9Sz4JHwibEkWaaoXSz4aKaT8DxcwGmjWg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>核心产品销售强劲]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>线下活动 | 生物医药知识产权新春研讨会，上海张江，3月20号</title><link>https://mp.weixin.qq.com/s/M062HbWOareG9UKTxNSsWQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropqNDSpuoia9sMjQtWpagW8mybg2hf0F9bsn5XPVX0mTsdyZnad6S9EtA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>欢迎生物医药企业知识产权/法务参与交流、席位有限。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>《创新药物研发经纬》顺利出版 ——国内首部回顾和展望新药研发何去何从的专著</title><link>https://mp.weixin.qq.com/s/R_j-a5k9AxBObnABTElk6Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu0UnoH91yzvrqibWPygzDUv0ibPyrLx1DLCDfU7WONSIsyGdiaGurtrcY39hAyQLfx1dfNciameI1ic08g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>新药研发体现了多学科交叉的高新技术创新和集成，是当代科技和经济国际竞争的战略制高点之一。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>药渡招聘 | 药学分析师</title><link>https://mp.weixin.qq.com/s/vJwMRuD9_kzeWT-vwH6mlw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu2SbXz3EPfLVa6wFpYoiapu5kz7Ffv8Bzvj5ATrAshUjEiamn7mXUFtglootBqicP9jZOX7k9x4HuzTA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药渡欢迎每一位致力于医药数据的有志之士！]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:00:16 +0800</pubDate></item><item><title>波生坦：构效关系+试错探索——地毯式的探索历程</title><link>https://mp.weixin.qq.com/s/0qrqVpbbCsFNqPNs6kxMUQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu1pbQMFunWxrP0fE7eCrwWNMOe79fAVibEFSYMORVoRz0iadHdibB0BIBWHnDOzDIfRyxGtwVLhPb7nQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>波生坦由瑞士爱克泰隆公司开发，首先于2001年获美国FDA批准，是治疗肺动脉高压的首创药物。]]></content:encoded><pubDate>Sun, 28 Feb 2021 21:54:49 +0800</pubDate></item><item><title>Science：CRISPR技术追踪癌细胞转移动态，为抗癌药物研究开辟新方向</title><link>https://mp.weixin.qq.com/s/qjz4B9wGiKLi4jXzGo1CRw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropfubgJPGVxyBbLmj26878hr3MnTBNibPPd8bQIDX5RFAkJsGja8s19fQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>揭示了癌症转移的发展和进展背后的动态过程]]></content:encoded><pubDate>Sun, 28 Feb 2021 21:54:49 +0800</pubDate></item><item><title>中山大学生科院研究发现：小分子中药阿可拉定下调肝癌髓源免疫抑制细胞（MDSC）的产生和激活</title><link>https://mp.weixin.qq.com/s/p4UVXaUHEszr9f2S-E0YCw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropuY222hGjO8dSyMgojcaBcMANNMnWtJHSc0SnZe51AXYpQQ2gkUicpSg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>阿可拉定是北京盛诺基医药科技股份有限公司自主研发的治疗肝细胞癌的创新药物，是多靶点的免疫调节小分子。]]></content:encoded><pubDate>Sun, 28 Feb 2021 21:54:49 +0800</pubDate></item><item><title>Cytiva赋能生物制药系列课程第2课：加速新型抗体药物开发策略</title><link>https://mp.weixin.qq.com/s/13ib7tlmdJI8nupdIZs3bg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu0aMOyicsgDX1DR1hBL5ibIicHQb5AMh5SsTzJPfeF7MByRiarh7QQct6Iial770pahUISO8WYrHMhYgag/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>3月3日晚19:30，直播间不见不散！]]></content:encoded><pubDate>Sun, 28 Feb 2021 21:54:49 +0800</pubDate></item><item><title>新书推荐 | 《药物合成——路线设计策略和案例解析》</title><link>https://mp.weixin.qq.com/s/lJqpWGiJFEaUx4ps3EVaeg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropc6gNkQ6Tbiav7BUoTLpbLQ7ncdn45nG7pUIlcR99sUb81s3RlLUn6IQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>新药研发流程、药物结构设计策略、药物合成方法和技术]]></content:encoded><pubDate>Sun, 28 Feb 2021 21:54:49 +0800</pubDate></item><item><title>药渡招聘 | 医药产品经理</title><link>https://mp.weixin.qq.com/s/M8v0qwSNjYfi6R0YMoBC1A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu2SbXz3EPfLVa6wFpYoiapu5kz7Ffv8Bzvj5ATrAshUjEiamn7mXUFtglootBqicP9jZOX7k9x4HuzTA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药渡欢迎每一位致力于医药数据的有志之士！]]></content:encoded><pubDate>Sun, 28 Feb 2021 21:54:49 +0800</pubDate></item><item><title>再生元First-in-class降脂新药Evinacumab获FDA批准</title><link>https://mp.weixin.qq.com/s/BcXPj5BbTD_efTvRUK92sw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropPIoCmN2ON22uq7CT6lBFM1NtCctmoQ82tcyFzRYib9lReQwKXtgOkrg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药渡出品]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:26:11 +0800</pubDate></item><item><title>两篇Ann Oncol解读！二甲双胍或会影响2型糖尿病女性患者的乳腺癌风险！</title><link>https://mp.weixin.qq.com/s/Vo6CpotkdObVhYWTG5i06w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropea8yLbVZNkN7VTEwl3CbyvNYEDiaTyEicmAaezStRQnANvleSQCgC59w/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>文章来源 | 生物谷日前，发表在国际杂志Annals of Oncology上的两篇研究报告中，来自美国国立]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:26:11 +0800</pubDate></item><item><title>一病一图 | 变应性鼻炎的临床用药竞争格局</title><link>https://mp.weixin.qq.com/s/GqiauE9P1FX8SjJgEhB-Jw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446ropI24mfGAEnrtjmpduo1df11SsDKOawVSjhWHVOjsicsmOnrDNhAQSr9g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药渡数据带你看清市场格局！]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:26:11 +0800</pubDate></item><item><title>细胞基因治疗专题会嘉宾阵容大公开！500余位知名药企/临床等行业人士加盟，火热报名中</title><link>https://mp.weixin.qq.com/s/YZERsm8S-RTkeLfymZehJA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446rop4HQ5FeIT7K8ibicJjyr33J3RMvDbpSlBecNHZaKb0Nw4UgWXRreILphw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>群英荟聚！4月申城登陆，细胞/基因治疗热火朝天，你还不来看看？]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:26:11 +0800</pubDate></item><item><title>好书推荐 | 系统生物学与中药方剂现代研究</title><link>https://mp.weixin.qq.com/s/p0OJLs6kHOus1sJke9yrMA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu324zJKic7m1H9YT81ibkiclu3uqnWNtmiaV0Yqy3A3bcHm00SW4BMpey8uCB2w8Au6cyyQalotibFI57A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>随着科学技术的进步，中医药的科学内涵逐渐被挖掘、认识，一系列领先国际前沿的科研成果使中医药正逐步被认可。]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:26:11 +0800</pubDate></item><item><title>全球首款化疗骨髓保护新药Trilaciclib，不一样的CDK4/6抑制剂</title><link>https://mp.weixin.qq.com/s/IIBPhPOBB1F2_T8FVINcfg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446rop1QFpzxxkgfiaMpG4tUeICvRkhWBzeDYkV310cl3vVbThLOWGwkBhv8Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药渡出品]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:49:04 +0800</pubDate></item><item><title>甘莱宣布THR-β激动剂ASC41 NASH适应症美国临床试验申请获批及全球开发计划的启动</title><link>https://mp.weixin.qq.com/s/3-FN3m6gDUqZnrjvXETpKg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/dRGVUcLiaOu3doRFGPzmSw0G4FG446rop7Vib31ysKKN9UawcRMsfILrk3JBdOXjtadrsSKc5NYdyD8Yc2ECtthw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>歌礼]]></content:encoded><pubDate>Fri, 26 Feb 2021 18:49:04 +0800</pubDate></item></channel></rss>